Cholesterol Binding, Efflux, and a PDZ-interacting Domain of Scavenger Receptor-BI Mediate HDL-initiated Signaling
Overview
Authors
Affiliations
The binding of HDL to scavenger receptor-BI (SR-BI) mediates cholesterol movement. HDL also induces multiple cellular signals, which in endothelium occur through SR-BI and converge to activate eNOS. To determine the molecular basis of a signaling event induced by HDL, we examined the proximal mechanisms in HDL activation of eNOS. In endothelial cells, HDL and methyl-beta-cyclodextrin caused comparable eNOS activation, whereas cholesterol-loaded methyl-beta-cyclodextrin had no effect. Phosphatidylcholine-loaded HDL caused greater stimulation than native HDL, and blocking antibody against SR-BI, which prevents cholesterol efflux, prevented eNOS activation. In a reconstitution model in COS-M6 cells, wild-type SR-BI mediated eNOS activation by both HDL and small unilamellar vesicles (SUVs), whereas the SR-BI mutant AVI, which is incapable of efflux to SUV, transmitted signal by only HDL. In addition, eNOS activation by methyl-beta-cyclodextrin was SR-BI dependent. Studies of mutant and chimeric class B scavenger receptors revealed that the C-terminal cytoplasmic PDZ-interacting domain and the C-terminal transmembrane domains of SR-BI are both necessary for HDL signaling. Furthermore, we demonstrated direct binding of cholesterol to the C-terminal transmembrane domain using a photoactivated derivative of cholesterol. Thus, HDL signaling requires cholesterol binding and efflux and C-terminal domains of SR-BI, and SR-BI serves as a cholesterol sensor on the plasma membrane.
Huang Y, Hou X, Lv F, Gong Z Rev Cardiovasc Med. 2025; 26(2):26403.
PMID: 40026506 PMC: 11868875. DOI: 10.31083/RCM26403.
Exome wide association study for blood lipids in 1,158,017 individuals from diverse populations.
Koyama S, Yu Z, Choi S, Jurgens S, Selvaraj M, Klarin D medRxiv. 2024; .
PMID: 39371182 PMC: 11451673. DOI: 10.1101/2024.09.17.24313718.
Denimal D Antioxidants (Basel). 2024; 13(1).
PMID: 38247481 PMC: 10812436. DOI: 10.3390/antiox13010057.
Noflatscher M, Hunjadi M, Schreinlechner M, Sommer P, Lener D, Theurl M Biomedicines. 2023; 11(7).
PMID: 37509557 PMC: 10376979. DOI: 10.3390/biomedicines11071918.
HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy.
Linton M, Yancey P, Tao H, Davies S Circ Res. 2023; 132(11):1521-1545.
PMID: 37228232 PMC: 10213997. DOI: 10.1161/CIRCRESAHA.123.321563.